Penn study shows MRI may help identify appropriate liquid biopsy candidates
Credit: Penn Medicine
PHILADELPHIA – Tracking brain cancer with a blood test instead of a surgical biopsy may greatly improve quality of life for glioblastoma (GBM) patients and provide critical information for their care, but it is not feasible in all cases. Now new research from the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center shows brain imaging may be able to predict when a blood test known as a liquid biopsy would or would not produce clinically actionable information, allowing doctors to more efficiently guide patients to the proper next steps in their care. The key is the ability to image two things – the blood brain barrier and a type of immune cell called macrophages – which, this study found, correlate with the amount of circulating DNA in the bloodstream. The journal Neuro-Oncology Advances published the findings today.
About 12,000 Americans are diagnosed with GBM each year, making it the most common malignant primary brain tumor in adults. It’s also the deadliest, with a five-year survival rate between five and 10 percent. The tumors themselves usually contain multiple genetic mutations, which means treatments that focus on one target are normally only partially effective at best. Further, tracking these mutations over time can be difficult, since getting a new tissue sample requires a repeat brain surgery. This is a particularly important issue for GBM, since almost all patients experience a recurrence, and when the disease comes back, it often returns with a vastly different genetic makeup.
Liquid biopsy is an alternative way to monitor some cancers, including GBM. With a simple blood test, doctors can measure the amount of cfDNA – circulating DNA that cancer and other cells shed into the blood – as well as circulating tumor DNA (ctDNA), which is the DNA specifically shed by cancer. However, unlike other parts of the body, the brain is protected by what’s called the blood brain barrier, a security gate that controls what gets in and what gets out. Depending on how hard it is for circulating DNA to get in and out of the brain, there may not be evidence of disease in the blood, meaning a liquid biopsy is not helpful in all cases.
This study begins to address that problem by adding imaging to the equation. The researchers show that an MRI can actually provide a picture of how leaky the blood brain barrier is, and that the higher the volume of tumor with a leaky blood brain barrier, the higher the levels of cfDNA and ctDNA are likely to be in a patient’s blood.
The study also found a correlation between the amount of cfDNA and the density of macrophages – a type of white blood cell that make up a large percentage of the cells inside a GBM and represent a major barrier to the immune system fighting the tumor.
“By better understanding the macrophage makeup in a given patient’s tumor, researchers may be able to identify which patients are the best candidates for treatments targeted against macrophages, or for immunotherapy in general,” said the study’s lead author Seyed Ali Nabavizadeh, MD, an assistant professor of Radiology at Penn.
In addition to showing how imaging may predict the feasibility of liquid biopsy in GBM, the researchers say it also points to promise of what the combination can find. However, they say further study is needed to understand how this information can affect treatment outcome and disease progression.
“The more information we have about a tumor, the better. The combination of being able to measure the integrity of the blood brain barrier, understanding the density of macrophages, and tracking the tumor through liquid biopsy may be able to help us tailor our treatment decisions so that each patient is getting precision therapy that gives them the best chance of seeing a benefit,” said the study’s senior author Stephen Bagley, MD, MSCE, an assistant professor of Hematology-Oncology.
This study was performed in cooperation with the Glioblastoma Translational Center of Excellence at the Abramson Cancer Center. Additional Penn authors include Jeffrey B. Ware, Samantha Guiry, MacLean P. Nasrallah, Jazmine J. Mays, Jacob E. Till, Jasmin Hussain, Aseel Abdalla, Stephanie S. Yee, Zev A. Binder, Donald M. O’Rourke, Steven Brem, Arati S. Desai, Ronald Wolf, and Erica L. Carpenter.
The study was supported by the National Institutes of Health Institutional Clinical and Translational Science Award (UL1TR001878) and the McCabe Foundation Award of the University of Pennsylvania.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center–which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report–Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.